Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Patrick C Gedeon, Ph.D., M.D.


The research activities and funding listed below are automatically derived from NIH ExPORTER and other sources, which might result in incorrect or missing items. Faculty can login to make corrections and additions.
  1. F30CA196199 (GEDEON, PATRICK C) Mar 1, 2015 - Feb 28, 2019
    Systemic EGFRvIII-targeted bispecific antibody as immunotherapy for glioblastoma
    Role: Principal Investigator

Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
  1. Gedeon PC, Champion CD, Rhodin KE, Woroniecka K, Kemeny HR, Bramall AN, Bernstock JD, Choi BD, Sampson JH. Checkpoint inhibitor immunotherapy for glioblastoma: current progress, challenges and future outlook. Expert Rev Clin Pharmacol. 2020 Oct; 13(10):1147-1158. PMID: 32862726.
    Citations:    Fields:    Translation:HumansAnimals
  2. Gedeon PC, Streicker MA, Schaller TH, Archer GE, Jokinen MP, Sampson JH. GLP toxicology study of a fully-human T cell redirecting CD3:EGFRvIII binding immunotherapeutic bispecific antibody. PLoS One. 2020; 15(7):e0236374. PMID: 32735564.
    Citations: 2     Fields:    Translation:HumansAnimalsCells
  3. Schaller TH, Snyder DJ, Spasojevic I, Gedeon PC, Sanchez-Perez L, Sampson JH. First in human dose calculation of a single-chain bispecific antibody targeting glioma using the MABEL approach. J Immunother Cancer. 2020 04; 8(1). PMID: 32273346.
    Citations: 3     Fields:    Translation:HumansAnimalsCells
  4. Suryadevara CM, Desai R, Farber SH, Choi BD, Swartz AM, Shen SH, Gedeon PC, Snyder DJ, Herndon JE, Healy P, Reap EA, Archer GE, Fecci PE, Sampson JH, Sanchez-Perez L. Preventing Lck Activation in CAR T Cells Confers Treg Resistance but Requires 4-1BB Signaling for Them to Persist and Treat Solid Tumors in Nonlymphodepleted Hosts. Clin Cancer Res. 2019 01 01; 25(1):358-368. PMID: 30425092.
    Citations: 17     Fields:    Translation:HumansAnimalsCells
  5. Gedeon PC, Schaller TH, Chitneni SK, Choi BD, Kuan CT, Suryadevara CM, Snyder DJ, Schmittling RJ, Szafranski SE, Cui X, Healy PN, Herndon JE, McLendon RE, Keir ST, Archer GE, Reap EA, Sanchez-Perez L, Bigner DD, Sampson JH. A Rationally Designed Fully Human EGFRvIII:CD3-Targeted Bispecific Antibody Redirects Human T Cells to Treat Patient-derived Intracerebral Malignant Glioma. Clin Cancer Res. 2018 08 01; 24(15):3611-3631. PMID: 29703821.
    Citations: 11     Fields:    Translation:HumansAnimalsCells
  6. Suryadevara CM, Desai R, Abel ML, Riccione KA, Batich KA, Shen SH, Chongsathidkiet P, Gedeon PC, Elsamadicy AA, Snyder DJ, Herndon JE, Healy P, Archer GE, Choi BD, Fecci PE, Sampson JH, Sanchez-Perez L. Temozolomide lymphodepletion enhances CAR abundance and correlates with antitumor efficacy against established glioblastoma. Oncoimmunology. 2018; 7(6):e1434464. PMID: 29872570.
    Citations: 26     
  7. Reap EA, Suryadevara CM, Batich KA, Sanchez-Perez L, Archer GE, Schmittling RJ, Norberg PK, Herndon JE, Healy P, Congdon KL, Gedeon PC, Campbell OC, Swartz AM, Riccione KA, Yi JS, Hossain-Ibrahim MK, Saraswathula A, Nair SK, Dunn-Pirio AM, Broome TM, Weinhold KJ, Desjardins A, Vlahovic G, McLendon RE, Friedman AH, Friedman HS, Bigner DD, Fecci PE, Mitchell DA, Sampson JH. Dendritic Cells Enhance Polyfunctionality of Adoptively Transferred T Cells That Target Cytomegalovirus in Glioblastoma. Cancer Res. 2018 01 01; 78(1):256-264. PMID: 29093005.
    Citations: 24     Fields:    Translation:HumansCells
  8. Asciutto EK, Gedeon PC, General IJ, Madura JD. Structure and Dynamics Study of LeuT Using the Markov State Model and Perturbation Response Scanning Reveals Distinct Ion Induced Conformational States. J Phys Chem B. 2016 08 25; 120(33):8361-8. PMID: 27311999.
    Citations:    Fields:    Translation:Cells
  9. Suryadevara CM, Gedeon PC, Sanchez-Perez L, Verla T, Alvarez-Breckenridge C, Choi BD, Fecci PE, Sampson JH. Are BiTEs the "missing link" in cancer therapy? Oncoimmunology. 2015 Jun; 4(6):e1008339. PMID: 26155413.
    Citations: 27     
  10. Gedeon PC, Thomas JR, Madura JD. Accelerated molecular dynamics and protein conformational change: a theoretical and practical guide using a membrane embedded model neurotransmitter transporter. Methods Mol Biol. 2015; 1215:253-87. PMID: 25330967.
    Citations: 5     Fields:    Translation:Cells
  11. Congdon KL, Gedeon PC, Suryadevara CM, Caruso HG, Cooper LJ, Heimberger AB, Sampson JH. Epidermal growth factor receptor and variant III targeted immunotherapy. Neuro Oncol. 2014 Oct; 16 Suppl 8:viii20-5. PMID: 25342601.
    Citations: 10     Fields:    Translation:HumansAnimals
  12. Gedeon PC, Riccione KA, Fecci PE, Sampson JH. Antibody-based immunotherapy for malignant glioma. Semin Oncol. 2014 Aug; 41(4):496-510. PMID: 25173142.
    Citations: 9     Fields:    Translation:HumansAnimals
  13. Thomas JR, Gedeon PC, Madura JD. Structural dynamics of the monoamine transporter homolog LeuT from accelerated conformational sampling and channel analysis. Proteins. 2014 Oct; 82(10):2289-302. PMID: 24753369.
    Citations: 3     Fields:    Translation:HumansCells
  14. Choi BD, Gedeon PC, Sanchez-Perez L, Bigner DD, Sampson JH. Regulatory T cells are redirected to kill glioblastoma by an EGFRvIII-targeted bispecific antibody. Oncoimmunology. 2013 Dec 01; 2(12):e26757. PMID: 24475376.
    Citations: 17     
  15. Choi BD, Suryadevara CM, Gedeon PC, Herndon JE, Sanchez-Perez L, Bigner DD, Sampson JH. Intracerebral delivery of a third generation EGFRvIII-specific chimeric antigen receptor is efficacious against human glioma. J Clin Neurosci. 2014 Jan; 21(1):189-90. PMID: 24054399.
    Citations: 35     Fields:    Translation:HumansAnimalsCells
  16. Choi BD, Gedeon PC, Herndon JE, Archer GE, Reap EA, Sanchez-Perez L, Mitchell DA, Bigner DD, Sampson JH. Human regulatory T cells kill tumor cells through granzyme-dependent cytotoxicity upon retargeting with a bispecific antibody. Cancer Immunol Res. 2013 Sep; 1(3):163. PMID: 24570975.
    Citations: 20     Fields:    Translation:HumansCells
  17. Gedeon PC, Choi BD, Hodges TR, Mitchell DA, Bigner DD, Sampson JH. An EGFRvIII-targeted bispecific T-cell engager overcomes limitations of the standard of care for glioblastoma. Expert Rev Clin Pharmacol. 2013 Jul; 6(4):375-86. PMID: 23927666.
    Citations: 10     Fields:    Translation:HumansAnimalsCells
  18. Choi BD, Gedeon PC, Kuan CT, Sanchez-Perez L, Archer GE, Bigner DD, Sampson JH. Rational design and generation of recombinant control reagents for bispecific antibodies through CDR mutagenesis. J Immunol Methods. 2013 Sep 30; 395(1-2):14-20. PMID: 23806556.
    Citations: 3     Fields:    Translation:HumansCells
  19. Gedeon PC, Choi BD, Sampson JH, Bigner DD. Rindopepimut: anti-EGFRvIII peptide vaccine, oncolytic. Drugs Future. 2013 Mar; 38(3):147-155. PMID: 25663738.
    Citations: 11     
  20. Choi BD, Kuan CT, Cai M, Archer GE, Mitchell DA, Gedeon PC, Sanchez-Perez L, Pastan I, Bigner DD, Sampson JH. Systemic administration of a bispecific antibody targeting EGFRvIII successfully treats intracerebral glioma. Proc Natl Acad Sci U S A. 2013 Jan 02; 110(1):270-5. PMID: 23248284.
    Citations: 48     Fields:    Translation:AnimalsCells
  21. Thomas JR, Gedeon PC, Grant BJ, Madura JD. LeuT conformational sampling utilizing accelerated molecular dynamics and principal component analysis. Biophys J. 2012 Jul 03; 103(1):L1-3. PMID: 22828348.
    Citations: 15     Fields:    Translation:HumansAnimalsCells
  22. Gedeon PC, Indarte M, Surratt CK, Madura JD. Molecular dynamics of leucine and dopamine transporter proteins in a model cell membrane lipid bilayer. Proteins. 2010 Mar; 78(4):797-811. PMID: 19899168.
    Citations: 24     Fields:    Translation:Cells
Local representatives can answer questions about the Profiles website or help with editing a profile or issues with profile data. For assistance with this profile: HMS/HSDM faculty should contact feedbackcatalyst.harvard.edu. For faculty or fellow appointment updates and changes, please ask your appointing department to contact HMS. For fellow personal and demographic information, contact HMS Human Resources at human_resourceshms.harvard.edu. For faculty personal and demographic information, contact HMS Office for Faculty Affairs at facappthms.harvard.edu.
Gedeon's Networks
Click the
buttons for more information and interactive visualizations!
Concepts (100)
Co-Authors (2)
Similar People (60)
Same Department 
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.